← brief for 2026-08-19 · Slowing decline

Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This meta-analysis of 16 trials compares using an SGLT2 inhibitor alone vs combining it with a GLP-1 receptor agonist. The combination group had better kidney and heart outcomes, but the benefit was smaller than using each drug alone. The study used data from 1500 patients with CKD.

Who did this work

Banerjee M · Basu M · Mukhopadhyay P · Ghosh S

Source

Article · PubMed, the drug frontier · 2026 Aug 19
https://pubmed.ncbi.nlm.nih.gov/42616235/